Frankfurt
15.05.25 | 12:04
2,030 Euro
+1,00 % +0,020
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,045 | 2,060 | 16:12 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07:36 | CROSSJECT's ZENEO needle-free autoinjector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors | 34 | GlobeNewswire (Europe) | Press Release CROSSJECT's ZENEO® needle-free auto-injector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors... ► Artikel lesen | |
| CROSSJECT Aktie jetzt für 0€ handeln | |||||
| 07.05. | CROSSJECT provides updates on the EUA filing of ZEPIZURE | 2 | GlobeNewswire (USA) | ||
| 27.03. | CROSSJECT reports financial results for 2024 | 135 | GlobeNewswire (Europe) | Press Release CROSSJECT reports financial results for 2024 Continued satisfactory production of regulatory batches with a view to filing in Q2 2025.Recruitment of Tony Tipton as Chief Operating Officer... ► Artikel lesen | |
| 25.03. | CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO adrenal insufficiency program | 131 | GlobeNewswire (Europe) | Press Release CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program CROSSJECT enhanced its collaboration with Eton Pharmaceuticals,... ► Artikel lesen | |
| 18.03. | CROSSJECT achieves key ZEPIZURE manufacturing batch stability milestones | 1 | GlobeNewswire (USA) | ||
| 12.02. | Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board | 145 | GlobeNewswire (Europe) | Dijon, FRANCE, February 12, 2025 - 0730 (CET) - Crossject (ISIN: FR0011716265; Euronext Growth: ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free... ► Artikel lesen | |
| 19.12.24 | Crossject confirms ZEPIZURE supply chain readiness with another successful ISO audit for Quality Management System | 129 | GlobeNewswire (Europe) | Crossject successfully passes another ISO 13485 audit for sites in Dijon and Gray (France)Company is ramping up supply chain to prepare for commercialization in U.S. Dijon, France, December 19, 2024... ► Artikel lesen | |
| 11.12.24 | Crossject announces the pricing of its reserved capital increase and warrants issuance for an aggregate amount of EUR 7.2M | 2 | GlobeNewswire (USA) | ||
| 10.12.24 | Crossject launches reserved capital increase and warrants issuance for an aggregate amount of at least €7m | 1 | GlobeNewswire (USA) | ||
| 09.12.24 | Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement | 1 | GlobeNewswire (USA) | ||
| 22.10.24 | Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE ahead of filing U.S. Emergency Use Authorization | 145 | GlobeNewswire (Europe) | Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025Crossject expects to file... ► Artikel lesen | |
| 23.09.24 | Crossject reports financial results and business highlights for the first six months of 2024 | 266 | GlobeNewswire (Europe) | Available cash €5.95 million, up from €2.3 million on December 31, 2023Reports stable investments in R&D and consolidation of operating income from BARDACompany on track to successfully file for the... ► Artikel lesen | |
| 19.08.24 | Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE Epilepsy Rescue Treatment | 281 | GlobeNewswire (Europe) | Press Release Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment Experienced executive to lead preparations... ► Artikel lesen | |
| 18.07.24 | Crossject achieves key ZEPIZURE manufacturing milestone | 196 | GlobeNewswire (Europe) | Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing siteMilestone complements the satisfying results from previous batches under stability studies, and is... ► Artikel lesen | |
| 10.07.24 | Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO Epinephrine | 209 | GlobeNewswire (Europe) | Key contribution to the acceleration of the development of ZENEO® EpinephrineFinancial support includes mainly grants, as well as subsidized loansFrance 2030 Plan dedicated to supporting French companies... ► Artikel lesen | |
| 26.06.24 | Crossject elaborates on ZEPIZURE potential in light of landmark RAMPART study and its own, recently published, bioequivalence study | 268 | GlobeNewswire (Europe) | Landmark RAMPART study established midazolam intramuscular (IM) injection as a standard of care in the pre-hospital emergency management of epilepsy crises compared to traditional benzodiazepine... ► Artikel lesen | |
| 12.06.24 | Crossject appoints Dan Chiche, MD as Chief Medical Officer North America | 265 | GlobeNewswire (Europe) | Brings extensive experience in drug development in the U.S and internationally and in maximizing value of medical productsReinforces leadership team and expands presence in North AmericaSupports processes... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 42,450 | +1,63 % | BERENBERG stuft Fresenius SE auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Fresenius von 45 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Nach dem starken Jahresstart der Aktie hätten... ► Artikel lesen | |
| INTUITIVE SURGICAL | 496,00 | -2,11 % | Intuitive Surgical, Inc.: Intuitive Announces CEO Transition Effective July 1, 2025 | ||
| HIMS & HERS HEALTH | 49,830 | -9,00 % | Hims & Hers Stock Pulls Back After Strong Q1 Earnings, 115% Gain Over Past Month | ||
| SERNOVA BIOTHERAPEUTICS | 0,134 | -1,47 % | Sernova Biotherapeutics Inc: Sernova talks interim data from Cell Pouch trial | ||
| FAMICORD | 3,900 | 0,00 % | EQS-HV: FamiCord AG: Bekanntmachung der Einberufung zur Hauptversammlung am 25.06.2025 in https://ir.famicord.com/de/annual-general-meetings/ mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG | EQS-News: FamiCord AG
/ Bekanntmachung der Einberufung zur Hauptversammlung
FamiCord AG: Bekanntmachung der Einberufung zur Hauptversammlung am 25.06.2025 in https://ir.famicord.com/de/annual-general-meetings/... ► Artikel lesen | |
| GERATHERM MEDICAL | 3,160 | -3,95 % | Geratherm Medical verlängert Kurzarbeit in Geratal | Geratherm Medical verlängert die Kurzarbeit in der Fieberthermometerproduktion am Standort Geratal der Geratherm Medical Germany GmbH bis zum 31. Dezember 2025. Das Unternehmen verweist auf die anhaltend... ► Artikel lesen | |
| ALIGN TECHNOLOGY | 165,10 | -1,73 % | Align Technology-Aktie mit großen Kursgewinnen (161,2689 €) | Zu den großen Gewinnern am Aktienmarkt zählt heute das Wertpapier von Align Technology . Das Papier verteuert sich am Donnerstag deutlich. Zu den besten Performern an der Börse zählt aktuell die Align... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,045 | -1,32 % | NuGen Medical Devices - Lillys Geschichte: Ein Teenager aus Nordkanada… | ||
| PLUS THERAPEUTICS | 0,500 | -6,38 % | Plus Therapeutics Inc.: Plus Therapeutics' REYOBIQ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM) | Multiple long-term LM survivors in those patients receiving multiple doses of REYOBIQ RNA sequencing data show early tumor apoptosis and activation of innate immune responses Updated ReSPECT data... ► Artikel lesen | |
| CARDINAL HEALTH | 132,75 | -0,11 % | Cardinal Health Stock Outlook: Is Wall Street Bullish or Bearish? | ||
| RESMED | 221,90 | +0,36 % | Dividendenbekanntmachungen (08.05.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADDNODE GROUP AB SE0017885767 1,15 SEK 0,1052 EUR AG BARR PLC GB00B6XZKY75 0,1376 GBP 0,1617 EUR ALANTRA PARTNERS SA ES0126501131 - 0... ► Artikel lesen | |
| DAVITA | 124,95 | -0,24 % | DaVita Inc. Reveals Retreat In Q1 Profit | WASHINGTON (dpa-AFX) - DaVita Inc. (DVA) reported a profit for first quarter that decreased from the same period last yearThe company's bottom line totaled $162.92 million, or $2.00 per share.... ► Artikel lesen | |
| UNITEDHEALTH | 231,20 | -16,17 % | UnitedHealth Group-Aktie leicht im Minus (338,6583 €) | Im US-amerikanischen Wertpapierhandel liegt die Aktie der UnitedHealth Group gegenwärtig im Minus. Die Aktie notiert derzeit bei 381,59 US-Dollar. Die UnitedHealth Group-Aktie verzeichnet aktuell ein... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 48,530 | +0,79 % | GOLDMAN SACHS stuft Siemens Healthineers auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat das Kursziel für Siemens Healthineers von 60 auf 56 Euro gesenkt, aber die Einstufung auf "Neutral" belassen. Richard Felton passte... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 50,40 | +0,80 % | Fresenius Medical Care: Analysten pessimistisch - Die Kasse klingelt! |
CROSSJECT SA gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell +1,00 % bei einem Aktienkurs von 2,030 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CROSSJECT SA finden Sie auf Wallstreet Online.